Biotech & MedTech News
-
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
March 7, 2024 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
DIAGNOS Announces Grant of Stock Options
March 4, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement
March 4, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (“Voyageur” or the “Corporation”) and Applied Pharmaceutical…
-
Voyageur Pharmaceuticals Ltd. Announces Closing of Private Placement
March 1, 2024 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (“Voyageur” or the “Company”), a provider of innovative…
-
DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors
February 29, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX to Present at the Emerging Growth Conference on March 7, 2024 and Provides Corporate Update
February 29, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a…
-
FendX Announces Proposed Shares for Debt Settlement
February 28, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”), a…
-
DIAGNOS Announces Closing of First Tranche of Private Placement
February 27, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
FendX and Dunmore Continue Successful Collaboration to Further REPELWRAP(TM) Film Development with a Next Pilot Manufacturing Run
February 27, 2024 (Source) — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the “Company” or “FendX”) a nanotechnology…
-
Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR…
